Ariel Investments, LLC — Ariel Global Composite on Pharmaron Beijing Co., Ltd.
Thesis
Pharmaron beat earnings expectations and raised its full-year revenue forecast on strong orders in laboratory services, drug development and clinical research. Continued contract development and manufacturing growth underpins a more durable revenue trajectory. Ariel also identifies AI-enabled drug discovery as an incremental growth opportunity. An integrated platform covering much of the pharmaceutical value chain supports differentiation and potential re-rating.
“robust order growth across its laboratory services, contract development and manufacturing (CDMO) and clinical research platforms.”
Key risks
- The elevated order growth and CDMO momentum may not continue at the present pace.
- AI-enabled drug discovery is an incremental opportunity rather than an established contributor.
- China’s uneven economic recovery and market conditions could continue to affect sentiment.